{"nctId":"NCT00578929","briefTitle":"Safety and Efficacy of Olopatadine HCl Nasal Spray in 6-11 Year Old Patients","startDateStruct":{"date":"2007-09"},"conditions":["Seasonal Allergic Rhinitis"],"count":2388,"armGroups":[{"label":"Olopatadine 0.6% 1 Spray","type":"EXPERIMENTAL","interventionNames":["Drug: Olopatadine Hydrochloride Nasal Spray 0.6%"]},{"label":"Vehicle 1 spray","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Vehicle"]},{"label":"Olopatadine 0.6% 2 sprays","type":"EXPERIMENTAL","interventionNames":["Drug: Olopatadine Hydrochloride Nasal Spray 0.6%"]},{"label":"Vehicle 2 sprays","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Vehicle"]}],"interventions":[{"name":"Olopatadine Hydrochloride Nasal Spray 0.6%","otherNames":[]},{"name":"Vehicle","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male or female; minimum of 6 years of age and less than 12 years\n* 2 year history of seasonal allergic rhinitis\n\nExclusion Criteria:\n\n* Concurrent disease that might interfere with the investigation or evaluation of te study medication\n* Confirmed diagnosis of chronic rhinosinusitis within the last year\n* Asthma, with the exception of mild intermittent asthma\n* Anatomical nasal deformity\n* Nasal obstruction\n* Known non-responder to antihistamines for symptoms of Seasonal Allergic Rhinitis (SAR)\n* Chronic or intermittent use of of inhaled, oral, intramuscular intravenous corticosteroids ot topical steroids\n* Ocular disorder other that allergic conjunctivitis","healthyVolunteers":false,"sex":"ALL","minimumAge":"6 Years","maximumAge":"11 Years","stdAges":["CHILD"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percent Change From Baseline in the Reflective Total Nasal Symptom Score (TNSS)","description":"Total Nasal Symptom Score comprised of scoring each of the following symptoms: runny nose, stuffy nose, itchy nose, and sneezing. Each symptom was scored as a 0 (none), 1 (mild), 2 (moderate), or 3 (severe). The 4 individual symptom scores were then added together for a total nasal symptom score.\n\nThe percent change from baseline was defined as the average of the morning and evening severity scores for the sum of the assessments of the 4 individual scores averaged across all days.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-25.10","spread":"1.45"},{"groupId":"OG001","value":"-18.17","spread":"1.45"},{"groupId":"OG002","value":"-26.35","spread":"1.45"},{"groupId":"OG003","value":"-21.21","spread":"1.45"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in the Reflective Total Ocular Symptom Score (TOSS)","description":"Total Ocular Symptom Score comprised of scoring each of the following symptoms: itchy eyes and watery eyes. Each symptom was scored as a 0 (none), 1 (mild), 2 (moderate), or 3 (severe). The 2 individual symptom scores were then added together for a total ocular symptom score.\n\nThe percent change from baseline was defined as the average of the morning and evening severity scores for the sum of the assessments of the 2 individual scores averaged across all days.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-25.02","spread":"5.11"},{"groupId":"OG001","value":"-6.09","spread":"5.10"},{"groupId":"OG002","value":"-25.03","spread":"3.33"},{"groupId":"OG003","value":"-9.46","spread":"3.37"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":298},"commonTop":["Headache","Epistaxis"]}}}